Angry investors say Ocata Therapeutics undervalued in sale – The Boston Globe
|
Angry investors say Ocata Therapeutics undervalued in sale
The Boston Globe At issue is not only the sale price for Ocata, which has about 35 employees, but also its intellectual property in embryonic stem cells. Such cells can grow others that Ocata initially hopes to implant in the eyes of patients suffering from macular … |
